Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.

Journal of vascular and interventional radiology : JVIR·2026

Same author

Comprehensive Approach to Prostate Cancer Metastasis Mimics at Prostate-Specific Membrane Antigen PET/CT.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026

Same author

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Abdominal manifestations of multisystem diseases: a pattern-based imaging review.

Abdominal radiology (New York)·2026

Same author

Hierarchical organ aging signatures from routine abdominal CT add incremental disease risk stratification beyond blood biomarkers.

medRxiv : the preprint server for health sciences·2026

Same author

Clinical Validity of NETest2.0<sup>®</sup> in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567).

Cancers·2026

Search research articles

Related Experiment Video

Updated: May 28, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Mahmoud Singer¹, Jennifer Valerin², Zhuoli Zhang¹

¹Department of Radiological Sciences, School of Medicine, University of California, Irvine, CA 92617, USA.

|February 12, 2025

Summary

Classical dendritic cells (cDCs) and Natural Killer T (NKT) cells offer promising cellular immunotherapy for colorectal cancer (CRC). Combining these cells may overcome limitations of current treatments for advanced and metastatic CRC.

Keywords:

CRC NK cells NKT cells TME modulation cellular immunotherapy classical dendritic cells colorectal cancer tumor microenvironment

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: May 28, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Immunology
Oncology
Cellular Therapy

Background:

Colorectal cancer (CRC) presents a significant global health challenge, with poor prognoses for advanced and metastatic stages.
Current immunotherapies, like immune checkpoint inhibitors, have limited efficacy in metastatic CRC (mCRC).
Classical dendritic cells (cDCs) are crucial for immune recognition and antigen presentation in cancer.

Purpose of the Study:

To review the therapeutic potential of combining classical dendritic cells (cDCs) and Natural Killer T (NKT) cells for colorectal cancer (CRC).
To explore the biological roles, therapeutic strategies, clinical applications, and challenges of cDC-NKT cell therapy in CRC.

Main Methods:

Review of existing literature on cDCs, NKT cells, and their roles in colorectal cancer immunology.
Analysis of synergistic therapeutic strategies involving cDCs and NKT cells.
Examination of challenges posed by the tumor microenvironment.

Main Results:

cDCs are key in initiating anti-tumor immune responses through antigen presentation.
NKT cells bridge innate and adaptive immunity and interact with dendritic cells.
Synergistic cDC-NKT cell therapy shows potential for enhancing anti-tumor immunity in CRC.

Conclusions:

Combined cDC and NKT cell therapy represents a novel cellular immunotherapy approach for colorectal cancer.
This strategy offers potential new hope for patients with difficult-to-treat advanced or metastatic CRC.
Further research and clinical applications are warranted to harness the full potential of cDC-NKT cell-based therapies.